Clinical Trials Browser

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

Clinical Trials

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

CALCIFER

A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer

SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

AVESEC

Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors

A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer

OHAI-NMIBC-01

Neurological Function in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin-Based Therapy

Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors

UMT-UC

Current Status of Diagnosis and Treatment of Uroepithelial Carcinoma

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria

Urine DNA Methylation Detection for Hematuria Evaluation

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation